Key facts
- It has raised $70K; the latest was Later Stage VC ($20K) in Oct 2025.
- Notable investors include US National Science Foundation, FuturePlay, Aaron Levie, Ben Pasternak, Cory Levy — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Omios Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Omios Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Omios Biologics
Developer of oncolytic virus immunotherapies designed to defeat cancer using virus biology. The company is dedicated to creating therapies that harness the power of viruses to selectively target and destroy cancer cells, enabling oncology healthcare providers and researchers to access durable, resistance-free therapies with improved tolerability for patients with solid tumors.
- Sector
- Healthcare
- HQ
- Oakland, CA, United States
- Founded
- 2017
- Employees
- 5
- Website
- omiosbio.com/
- Ownership
- Privately Held (backing)
Omios Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omios Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omios Biologics in its N-PORT filings yet. We sweep new filings monthly.